Literature DB >> 14594443

Pharmacological management of neuropathic pain.

Gary McCleane1.   

Abstract

In health, the nervous system exists in a balance between inhibitory and excitatory influences. This balance may be upset if neural tissue is damaged or irritated and may give rise to neuropathic pain. Such neuropathic pain does not respond consistently to opioid analgesics or NSAIDs and it may therefore be necessary to utilise other therapeutic agents with known activity on either the excitatory or inhibitory components of the pain pathway. These other agents are traditionally considered with reference to their original uses; we still refer to tricyclic antidepressants (TCAs) and anticonvulsant drugs when a consideration of their modes of action may allow more rational use. For example, carbamazepine is related to the TCAs by virtue of its chemical structure and proposed mode of action and yet is still classified as an anticonvulsant drug. With respect to the opioids, increasing evidence points to an analgesic effect in neuropathic pain, although concerns regarding tolerance and dependence still prevent more widespread use. The anticonvulsants comprise a group of compounds possessing anticonvulsant and analgesic properties, but each possesses differing modes of action and so several members of the class should be tried before a conclusion is reached that they, as a whole, are ineffective. TCAs may also have a role in the treatment of neuropathic pain. As with all drugs, if their use is not associated with pain relief in a defined period of time, their use should be terminated. Topical TCAs may also have a role where the area of neuropathic pain is small. Other options, such as SSRIs, membrane stabilisers, capsaicin, baclofen and clonidine may have potential in treating neuropathic pain. The available evidence regarding the efficacy of currently available agents for the treatment of neuropathic pain is sparse. With the knowledge of achieving analgesia, according to the modes of actions of various agents it is hoped that the treatment of this difficult condition may be more logical and successful.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14594443     DOI: 10.2165/00023210-200317140-00003

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


  127 in total

1.  Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study.

Authors:  I Gilron; S L Booher; J S Rowan; M B Max
Journal:  Clin Neuropharmacol       Date:  2001 Mar-Apr       Impact factor: 1.592

2.  The effect of tramadol in painful polyneuropathy in relation to serum drug and metabolite levels.

Authors:  S H Sindrup; C Madsen; K Brøsen; T S Jensen
Journal:  Clin Pharmacol Ther       Date:  1999-12       Impact factor: 6.875

3.  Oral topical doxepin rinse: analgesic effect in patients with oral mucosal pain due to cancer or cancer therapy.

Authors:  J B Epstein; E L Truelove; H Oien; C Allison; N D Le; M S Epstein
Journal:  Oral Oncol       Date:  2001-12       Impact factor: 5.337

4.  Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Authors:  M B Max; S A Lynch; J Muir; S E Shoaf; B Smoller; R Dubner
Journal:  N Engl J Med       Date:  1992-05-07       Impact factor: 91.245

5.  Peripheral amitriptyline suppresses formalin-induced Fos expression in the rat spinal cord.

Authors:  Caroline E Heughan; Gary V Allen; Teena D Chase; Jana Sawynok
Journal:  Anesth Analg       Date:  2002-02       Impact factor: 5.108

6.  Gabapentin for relief of neuropathic pain related to anticancer treatment: a preliminary study.

Authors:  S Bosnjak; S Jelic; S Susnjar; V Luki
Journal:  J Chemother       Date:  2002-04       Impact factor: 1.714

7.  Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex.

Authors:  G Lees; M J Leach
Journal:  Brain Res       Date:  1993-05-28       Impact factor: 3.252

8.  Molecular mechanisms of the reversal of imipramine-induced sodium channel blockade by alkalinization in human cardiac myocytes.

Authors:  E Bou-Abboud; S Nattel
Journal:  Cardiovasc Res       Date:  1998-05       Impact factor: 10.787

9.  Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy.

Authors:  Phillip A Low; Tonette L Opfer-Gehrking; Peter J Dyck; William J Litchy; Peter C O'Brien
Journal:  Pain       Date:  1995-08       Impact factor: 6.961

10.  Noradrenergic and opioidergic influences on the antinociceptive effect of clomipramine in the formalin test in rats.

Authors:  M Ansuategui; L Naharro; M Feria
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

View more
  7 in total

1.  Acute and subchronic effects of amitriptyline on processing capacity in neuropathic pain patients using visual event-related potentials: preliminary findings.

Authors:  D S Veldhuijzen; J L Kenemans; A J M van Wijck; B Olivier; C J Kalkman; E R Volkerts
Journal:  Psychopharmacology (Berl)       Date:  2005-11-15       Impact factor: 4.530

2.  Preclinical Comparison of Mechanistically Different Antiseizure, Antinociceptive, and/or Antidepressant Drugs in a Battery of Rodent Models of Nociceptive and Neuropathic Pain.

Authors:  Misty D Smith; Jose H Woodhead; Laura J Handy; Timothy H Pruess; Fabiola Vanegas; Erin Grussendorf; Joel Grussendorf; Karen White; Karolina K Bulaj; Reisa K Krumin; Megan Hunt; Karen S Wilcox
Journal:  Neurochem Res       Date:  2017-05-15       Impact factor: 3.996

3.  Steady-state pharmacokinetics and pharmacodynamics of CHF3381, a novel antineuropathic pain agent, in healthy subjects.

Authors:  Béatrice Astruc; Antoine Tarral; Philippe Dostert; Fabrizia Mariotti; Laura Fabbri; Bruno P Imbimbo
Journal:  Br J Clin Pharmacol       Date:  2005-04       Impact factor: 4.335

4.  Intrathecal gabapentin enhances the analgesic effects of subtherapeutic dose morphine in a rat experimental pancreatitis model.

Authors:  Matthew M Smiley; Ying Lu; Louis P Vera-Portocarrero; Amr Zidan; Karin N Westlund
Journal:  Anesthesiology       Date:  2004-09       Impact factor: 7.892

Review 5.  An evidence-based algorithm for the treatment of neuropathic pain.

Authors:  Nanna B Finnerup; Marit Otto; Troels S Jensen; Søren H Sindrup
Journal:  MedGenMed       Date:  2007-05-15

Review 6.  Current management of pain associated with multiple sclerosis.

Authors:  Walter Pöllmann; Wolfgang Feneberg
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  Diclofenac Inhibits 27-hydroxycholesterol-induced Differentiation of Monocytic Cells into Mature Dendritic Cells.

Authors:  Yonghae Son; Bo-Young Kim; Young Chul Park; Koanhoi Kim
Journal:  Immune Netw       Date:  2017-06-20       Impact factor: 6.303

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.